Biotech Values

[DewDiligence]

Sounds like you’re blaming XOMA’s current management for the disclosures that XOMA’s former management did not make about AEs in the Gevokicumab diabetes trials. I suppose current management could release those data, but it’s not typical for a biotech company to focus investors’ attention—even indirectly—on defunct programs such as Gevokizumab for diabetes.